NCT05284799 - Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers. | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

May 9, 2022

Primary Completion Date

July 19, 2022

Study Completion Date

December 9, 2022

Conditions

Influenza

Interventions

BIOLOGICAL

OVX836 480µg

One single administration intramuscularly at Day 1

BIOLOGICAL

Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)

One single administration intramuscularly at Day 1

BIOLOGICAL

Placebo

One single administration intramuscularly at Day 1

Trial Locations (1)

Northern Beaches Clinical Research, Brookvale